118 related articles for article (PubMed ID: 2438715)
21. [The prognosis of Graves' disease after antithyroid drug treatment: clinical significance of the T3 suppression test and abnormal thyroid stimulators].
Iida Y; Konishi J; Kasagi K; Misaki T; Endo K; Nesumi N; Torizuka K; Tanaka K; Ishii H; Naito K; Nishikawa M; Inada M; Imura H; Kuma K
Nihon Naibunpi Gakkai Zasshi; 1982 Jun; 58(6):796-806. PubMed ID: 6180937
[TBL] [Abstract][Full Text] [Related]
22. Optimization and clinical assessment of a radioreceptor assay for thyrotropin-binding inhibitor immunoglobulins.
Konishi J; Kasagi K; Iida Y; Kousaka T; Misaki T; Arai K; Tokuda Y; Torizuka K
Endocrinol Jpn; 1987 Feb; 34(1):13-20. PubMed ID: 2440665
[TBL] [Abstract][Full Text] [Related]
23. Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs.
Kim TY; Park YJ; Park DJ; Chung HK; Kim WB; Kohn LD; Cho BY
J Clin Endocrinol Metab; 2003 Jan; 88(1):117-24. PubMed ID: 12519839
[TBL] [Abstract][Full Text] [Related]
24. Evidence of a correlation between thyrotrophin receptor binding inhibition and thyroid adenylate cyclase activation by immunoglobulins in Graves' disease before and during long-term antithyroid treatment.
Bliddal H; Bech K; Hyltoft Petersen P; Siersbaek-Nielsen K; Friis T
Acta Endocrinol (Copenh); 1982 Sep; 101(1):35-40. PubMed ID: 6181640
[TBL] [Abstract][Full Text] [Related]
25. Determination of thyroid stimulating immunoglobulins (TSI) during the course of Graves' disease. A reliable indicator for remission and persistence of this disease?
Schleusener H; Finke R; Kotulla P; Wenzel KW; Meinhold H; Roedler HD
J Endocrinol Invest; 1978 Apr; 1(2):155-61. PubMed ID: 90689
[No Abstract] [Full Text] [Related]
26. A patient with Graves' disease who developed hypothyroidism associated with thyroid stimulation blocking immunoglobulin during anti-thyroid drug therapy.
Inomata H; Tsuyusaki T; Sasaki N; Tamaru K; Niimi H; Nakajima H
Endocrinol Jpn; 1988 Jun; 35(3):379-84. PubMed ID: 2461854
[TBL] [Abstract][Full Text] [Related]
27. ANCA in Graves' disease--is it antithyroid medication-induced?
Prakash EB
J Assoc Physicians India; 2009 Jul; 57():545; author reply 545. PubMed ID: 20329422
[No Abstract] [Full Text] [Related]
28. TSH-receptor antibodies in mothers with Graves' disease and outcome in their offspring.
Matsuura N; Konishi J; Fujieda K; Kasagi K; Iida Y; Hagisawa M; Fujimoto S; Fukushi M; Takasugi N
Lancet; 1988 Jan 2-9; 1(8575-6):14-7. PubMed ID: 2891888
[TBL] [Abstract][Full Text] [Related]
29. The challenge of treating Graves'-Basedow's disease patients with antithyroid drugs (ATD) in a large university hospital.
Iacona A; Lima N; Perozim LM; Knobel M; Cavaliere H; Medeiros-Neto G
Exp Clin Endocrinol; 1991 May; 97(2-3):297-302. PubMed ID: 1717299
[No Abstract] [Full Text] [Related]
30. The long-term follow-up of patients with thionamide-treated Graves' hyperthyroidism.
Bandai S; Okamura K; Fujikawa M; Sato K; Ikenoue H; Kitazono T
Endocr J; 2019 Jun; 66(6):535-545. PubMed ID: 30918165
[TBL] [Abstract][Full Text] [Related]
31. Immunological parameters in Graves' disease: are they useful for indication and monitoring of antithyroid drug treatment?
Orgiazzi J; Madec AM; Genetet N; Gueguen M; Allannic H
Horm Res; 1987; 26(1-4):131-6. PubMed ID: 2439426
[TBL] [Abstract][Full Text] [Related]
32. Circulating immune complexes and thyroid-stimulating immunoglobulins before, during, and after antithyroid drug therapy in patients with Graves' disease.
van der Heide D; Daha MR; Bolk JH; Bussemaker JK; de Bruin TW; Goslings BM; van Es LA; Querido A
Lancet; 1980 Jun; 1(8183):1376-9. PubMed ID: 6155582
[TBL] [Abstract][Full Text] [Related]
33. Quantitative measurement of anti-TSH receptor antibodies is useful for the evaluation of treatment effect.
Amino N; Kubota S; Morita S; Fukata S; Miyauchi A
Thyroid; 2007 Jan; 17(1):85-6. PubMed ID: 17274759
[No Abstract] [Full Text] [Related]
34. [Guideline for the treatment of Graves' disease with antithyroid drug].
Nakamura H
Nihon Rinsho; 2006 Dec; 64(12):2189-93. PubMed ID: 17154077
[TBL] [Abstract][Full Text] [Related]
35. [Theoretical aspects of the treatment with antithyroid drugs].
Orgiazzi J; Millot L
Ann Endocrinol (Paris); 1994; 55(1):1-5. PubMed ID: 7528484
[TBL] [Abstract][Full Text] [Related]
36. Medical aspects on surgery in Graves' disease. Clinical review.
Karlsson FA; Winsa B; Rastad J; Johansson H
Acta Chir Scand; 1990 Jan; 156(1):47-51. PubMed ID: 1690941
[No Abstract] [Full Text] [Related]
37. Evidence that antithyroid drugs induce remissions in Graves' disease by modulating thyroid cellular activity.
Volpé R; Karlsson A; Jansson R; Dahlberg PA
Clin Endocrinol (Oxf); 1986 Oct; 25(4):453-62. PubMed ID: 2441908
[No Abstract] [Full Text] [Related]
38. How antithyroid drugs work in Graves' disease.
Weetman AP
Clin Endocrinol (Oxf); 1992 Oct; 37(4):317-8. PubMed ID: 1282852
[No Abstract] [Full Text] [Related]
39. Detection of thyroid-stimulating antibodies in sera of patients with Graves' disease--clinical and experimental studies.
Chen G; Ye WX
J Tongji Med Univ; 1987; 7(1):35-9. PubMed ID: 2885423
[No Abstract] [Full Text] [Related]
40. Carbimazole treatment in smokers vs nonsmokers with Graves disease.
Shin JI; Lee JS
JAMA; 2009 May; 301(19):1988-9; author reply 1989. PubMed ID: 19454634
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
